by Thomas R. Collins: Early results show that venetoclax, a BCL-2-inhibitor, produced relatively good response rates in relapsed or refractory non-Hodgkin lymphoma (NHL) patients.1
by Thomas R. Collins: There could be a role for consolidation autologous stem cell transplantation for patients with diffuse, aggressive non-Hodgkin lymphomas (NHL) who are at high risk… read more.
by Thomas R. Collins: Trials are continuing to explore potential new settings for daratumumab and elotuzumab, two monoclonal antibodies that were recently approved for use in multiple myeloma… read more.
by Bruce Sylvester: Treatment with nicotinamide, a form of vitamin B3, significantly lowers the risk of common, non-melanoma skin cancer in high-risk patients, researchers reported on Oct. 21,… read more.
by Thomas R. Collins: Studies on PD-1 blockade in classical Hodgkin lymphoma are still only entering Phase 2, but the early results and a history of success in… read more.
by Thomas R. Collins: Five years after the last patient’s last treatment visit, the final results are in for brentuximab vedotin’s (BV) pivotal Phase 2 study, offering perhaps… read more.
by Thomas R. Collins: Researchers have developed a prognostic “score” to gauge the chances of progression-free survival in patients with relapsed or refractory Hodgkin lymphoma who have had… read more.
by Bruce Sylvester: Anastrozole appears to be as effective as tamoxifen in treating ductal carcinoma in situ (DCIS), a very early form of breast cancer, and could offer… read more.
by Bruce Sylvester: Surgical resection is a safe and helpful treatment option for a broad range of patients with early-stage lung cancer, researchers reported online on Nov. 10,… read more.
The majority of patients presenting with MM are elderly and pose a considerable clinical challenge in terms of disease burden and comorbidities compared with their younger counterparts. A… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
